Last reviewed · How we verify
PRJ1-3024
At a glance
| Generic name | PRJ1-3024 |
|---|---|
| Sponsor | Zhuhai Yufan Biotechnologies Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (PHASE1)
- A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRJ1-3024 CI brief — competitive landscape report
- PRJ1-3024 updates RSS · CI watch RSS
- Zhuhai Yufan Biotechnologies Co., Ltd portfolio CI